MiR-582-5p blocks NSCLC metastasis by targeting mitogen-activated protein kinase kinase kinase 2, and it shows the potential to be an independent prognostic biomarker for patients with NSCLC[37]. The gene discussed is MAP2K2; the disease is non-small cell lung carcinoma.